Shots:
The US FDA approved multiple novel drugs in September 2026 across rare diseases, oncology, neurology, diabetes, and precision medicine, with approvals from companies including Ionis, AstraZeneca, Scholar Rock, Lilly, AbbVie, and Egetis.
Key approvals included Zanvastro for Alexander disease, Etcamah for ESR1-mutated advanced breast cancer, Isembyld for spinal muscular atrophy, Onswik for type 2…
